TransMedics Group upgraded by Needham with a new price target
$TMDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Needham upgraded TransMedics Group from Hold to Buy and set a new price target of $148.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2026 | Outperform → Perform | Oppenheimer | |
| 10/23/2025 | $148.00 | Hold → Buy | Needham |
| 10/13/2025 | $145.00 | Buy | Jefferies |
| 9/16/2025 | $155.00 | Outperform | Evercore ISI |
| 9/4/2025 | $115.00 | Hold | Stifel |
| 12/17/2024 | $116.00 → $75.00 | Overweight → Neutral | Analyst |
| 11/22/2024 | Buy → Hold | Needham | |
| 10/29/2024 | $200.00 → $125.00 | Outperform | Oppenheimer |
Oppenheimer downgraded TransMedics Group from Outperform to Perform
Needham upgraded TransMedics Group from Hold to Buy and set a new price target of $148.00
Jefferies initiated coverage of TransMedics Group with a rating of Buy and set a new price target of $145.00
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
SD - TransMedics Group, Inc. (0001756262) (Filer)
8-K - TransMedics Group, Inc. (0001756262) (Filer)
DEFA14A - TransMedics Group, Inc. (0001756262) (Filer)
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 23,171 shares of TransMedics' common stock and 15,409 restricted stock units granted to Matthew S. Forsyth, the Co
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The TransMedics management team will present beginning at 2:20 p.m. ET/ 1:20 p.m. CT. A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsTotal revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026Adjusted net income of $10.9 million or $0.30 per fully dilut
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1. S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda
ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsTotal revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026Adjusted net income of $10.9 million or $0.30 per fully dilut
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic c
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m